We are pleased at the opportunity to extend our collaboration with Teva beyond the three transactions we have previously completed in the last eighteen months. Robert W. Schrepfer, VP of Business Advancement, commented, This transaction additional illustrates ANI's capability to execute strategic acquisitions that leverage our internal capabilities and expand our approved item portfolio. We are fortunate to have developed this strategic relationship with a business leader such as for example Teva. .. ANI acquires 22 previously marketed generic drug items for $25 million from Teva Pharmaceuticals ANI Pharmaceuticals, Inc.There are no medications approved to take care of GA connected with dry AMD. Emixustat hydrochloride is being studied to determine whether it slows the progression of GA in sufferers with GA connected with dry AMD.S. Food and Drug Administration . ARVO shall be held within Seattle, Washington from May 5-9, 2013. ‘Acucela is focused on developing fresh and innovative ophthalmic products where there exists an unmet or underserved medical want and emixustat hydrocholoride is definitely a prime exemplory case of this dedication,’ mentioned Ryo Kubota, MD, PhD, chairman, president and CEO, Acucela Inc. ‘Today's announcement represents a significant milestone for not only Acucela, but also for the emixustat hydrochloride plan and potentially for sufferers worldwide.